Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation

INDIANAPOLIS – (June 4, 2024) – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues its mission to reduce workflow times and grueling manual steps with the launch of its new Valita Aggregation Pure assay. The plate-based 96-well screening tool offers rapid, high-throughput protein aggregation detection and quantification, providing robust aggregation data in as little as 15 minutes.

Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation

Image Credit: Beckman Coulter Life Sciences

​​​​​​Traditional workflows in monoclonal antibody production require long wait times of up to six hours to determine protein aggregation levels. The new Valita Aggregation Pure assay from Beckman Coulter Life Sciences cuts through the clutter, delivering a rapid solution that is among the fastest and simplest aggregation detection tools on the market, and is compatible with high-performance microplate readers with fluorescence polarization functionality.

“Processing thousands of samples to generate a commercially viable cell line is a complex and tedious process that can slow laboratory workflows,” said Dr. Elisa Nent, Global Product Manager - Cell Health. “We continue to hear the critical need to rapidly measure antibody aggregation faster than traditional DLS/SLS and HPLC-SEC methods. Our innovation slashes manual steps, the need for additional reagents, and added expense – all in a fraction of the time. We’re confident this will allow laboratory staff to get results faster and focus their efforts on critical research goals.”

The new assay enhances the process development workflow by enabling detection and quantification of antibody aggregation at any stage of time. In less than 15 minutes, aggregation can be quantified by simply adding purified samples to the plate, incubating at room temperature, and measuring aggregation using a plate reader. Available as 96-well plates and validated with samples concentrated between 200-2,000 milligrams per liter, with a detection limit of 0.5% aggregation at 1,000 milligrams per liter, it enables rapid, high-throughput protein aggregation analysis. Learn more about the Valita Aggregation Pure Assay by clicking here.

About Beckman Coulter Life Sciences

With a relentless mission to empower those seeking answers to life’s important scientific questions, Beckman Coulter Life Sciences is a preferred laboratory partner providing automation and innovation solutions for Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling workflows. With a legacy dating back to 1935, our technologies reduce manual laboratory processes and can provide greater speed, accuracy, and advanced analytics to accelerate answers with a guiding focus to improve patient care and enable pioneering discoveries.

Beckman Coulter Life Sciences is headquartered in Indianapolis, Indiana with 11 operational hubs around the world and employs approximately 2,800 associates with more than 400,000 systems installed globally. Get to know us by clicking here and by following us on LinkedIn.

Valita,Valita Aggregation Pure are trademarks or registered trademarks of ValitaCell Ltd in the United States and other countries. ValitaCell is a Beckman Coulter Company. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Beckman Coulter Life Sciences - Flow Cytometry. (2024, June 05). Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation. News-Medical. Retrieved on July 16, 2024 from https://www.news-medical.net/news/20240605/Beckman-Coulter-Life-Sciences-Releases-Innovative-Assay-to-Quantify-Antibody-Aggregation.aspx.

  • MLA

    Beckman Coulter Life Sciences - Flow Cytometry. "Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation". News-Medical. 16 July 2024. <https://www.news-medical.net/news/20240605/Beckman-Coulter-Life-Sciences-Releases-Innovative-Assay-to-Quantify-Antibody-Aggregation.aspx>.

  • Chicago

    Beckman Coulter Life Sciences - Flow Cytometry. "Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation". News-Medical. https://www.news-medical.net/news/20240605/Beckman-Coulter-Life-Sciences-Releases-Innovative-Assay-to-Quantify-Antibody-Aggregation.aspx. (accessed July 16, 2024).

  • Harvard

    Beckman Coulter Life Sciences - Flow Cytometry. 2024. Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation. News-Medical, viewed 16 July 2024, https://www.news-medical.net/news/20240605/Beckman-Coulter-Life-Sciences-Releases-Innovative-Assay-to-Quantify-Antibody-Aggregation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Beckman Coulter Life Sciences announces contest, products for centrifugation milestone